Kura Oncology (NASDAQ:KURA) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Kura Oncology (NASDAQ:KURA) released its quarterly earnings results on Thursday. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03), Briefing.com reports. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the company posted ($0.50) EPS.

Kura Oncology Price Performance

Shares of KURA traded up $0.04 during mid-day trading on Friday, hitting $20.63. The company’s stock had a trading volume of 605,625 shares, compared to its average volume of 1,285,810. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.26 and a quick ratio of 12.26. The firm has a 50-day moving average price of $20.65 and a 200 day moving average price of $15.85. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -9.92 and a beta of 0.89.

Wall Street Analyst Weigh In

Several research analysts have commented on KURA shares. Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research report on Friday. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, April 15th. JMP Securities lifted their target price on Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a research note on Wednesday, January 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $28.28.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.